The Federal Supreme Court confirmed the Federal Patent Court’s three-step function, accessibility and equal value test to analyse infringement under the doctrine of equivalents. A full summary of this case has been published on Kluwer IP Law.
The Patent Trial and Appeal Board did not err in finding that certain claims of Slot Speaker Technologies, Inc.’s sound reproduction system patent were invalid as obvious in light of prior art, according to the U.S. Court of Appeal for the Federal Circuit. However, the Board erred in holding that a third claim was not…
The Court of Appeal dismissed Boehringer Ingelheim’s application for permission to appeal the first instance Patents Court decision that EP (UK) 1,379,220 lacked inventive step. The Court of Appeal also considered and overturned the existing judicial guidance on granting permission to appeal in patent matters. A full summary of this case has been published on…
In this case the FCJ considered the question of when the enforcement of a judgment in an infringement action should be suspended in light of a decision of the Federal Patent Court in a parallel nullity action concerning the same patent. The Court held that there is no reason for a suspension if the patent…
The Bulgarian Supreme Administrative Court upheld a first instance judgment annulling the decision of the Bulgarian Patent Office to refuse the grant of a supplementary protection certificate for a medical product where the active ingredient was functionally defined in the patent claims rather than through its structural formula. A full summary of this case has…
by Bernward Zollner for rospatt osten pross In a recent decision of 10 January 2017 (BGH X ZR 17/13) concerning a “Restitutionsklage” against a final patent infringement judgement of the Appeal Court Düsseldorf the German “Bundesgerichtshof” has broadened the scope of the doctrine which the court has developed under the heading “Crimp-Werkzeug”. This doctrine was…
Pharmaceuticals company Watson’s proposed generic version of competitor Shire’s brand-name mesalamine LIALDA® did not satisfy the requirements for a Markush group claimed by a Shire patent, the U.S. Court of Appeals for the Federal Circuit has held. A compound contained in the ANDA product—which was not present in the patent claim’s Markush group—structurally and functionally…
Provisional measures, notably the interlocutory injunction provided for by Article 338-I of the Portuguese Code of Industrial Property, do not extend to the provisional protection of a European patent, nor to a national patent the translation of which is not yet published, because there is an insufficent degree of fumus boni iuris as the protection…
In relation to a dispute concerning the novelty of one invention, the Court held that testing a new product in a special laboratory under contract is not public as such. The testing process and its results are not usually available to third parties, so it cannot be equated to disclosure of information about the product…
The court upheld the decision that the patent applications in question had been appropriately considered and that the examiner had established that there were formal reasons for refusing the patent applications. It also ruled that since the patent applications had been refused solely on formal grounds, the Plaintiff still had the right to file those…
